

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Atezolizumab with bevacizumab for untreated unresectable or advanced hepatocellular carcinoma ID1655

Provisional stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Roche (Atezolizumab, bevacizumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Black Health Agency • British Liver Trust • Cancer Black Care • Cancer Equality • Cancer 52 • Helen Rollason Cancer Charity • Hepatitis B Foundation UK • Hepatitis C Trust • Independent Cancer Patients' Voice • Liver4Life • Macmillan Cancer Support • Maggie's Centres • Marie Curie • Muslim Council of Britain • Pelican Cancer Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Anaesthetists • Association of Cancer Physicians • Association of Surgeons of Great Britain and Ireland • British Association of the Study of the Liver • British Geriatrics Society • British Institute of Radiologists • British Liver Nurses Association • British Psychosocial Oncology Society • British Society of Gastroenterology • Cancer Research UK • Hepatitis Nurse Specialist Forum 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • All Wales Therapeutics and Toxicology Centre • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible Comparator companies</u></p> <ul style="list-style-type: none"> • Bayer PLC (sorafenib) • Eisai Ltd (lenvatinib) <p><u>Relevant Research groups</u></p> <ul style="list-style-type: none"> • Cochrane Hepato-biliary Group • Cochrane Infectious Diseases Group • Foundation for Liver Research • Guts UK • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research <p><u>Associated Public Health Groups</u></p>

Provisional stakeholder list for the technology appraisal of atezolizumab with bevacizumab for untreated unresectable or advanced hepatocellular carcinoma ID1655. Issue date: September 2019

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiologists • UK Clinical Pharmacy Association • UK Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Nene CCG • NHS West Suffolk CCG • NHS England • Welsh Government 	<ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Documentation (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Documentation (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and, and the British National Formulary.

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.